Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial
Helen A Dakin, Sarah Wordsworth, Chris A Rogers, Giselle Abangma, James Raftery, Simon P Harding, Andrew J Lotery, Susan M Downes, Usha Chakravarthy, Barnaby C Reeves, on behalf of the IVAN Study Investigators
BMJ Open Jul 2014, 4 (7) e005094; DOI: 10.1136/bmjopen-2014-005094